Targeted radionuclide therapy using VHH pretargeting platform

Targeted radionuclide therapy (TRT) is a promising systemic treatment modality for cancer, offering high specificity and therapeutic potential. While peptide-based radiopharmaceuticals have proven successful in clinical practice, particularly in late-stage patients, the use of antibody- and biologic-based radiopharmaceuticals is often limited by hematotoxicity or nephrotoxicity. This project aims to overcome these limitations by developing a pretargeting strategy based on a VHH (single-domain antibody) platform. The research will focus on the design and optimization of the non-radioactive vector molecule, the pretargeting approach, and radiochemistry. The ultimate goal is to improve the therapeutic index of TRT, enabling treatment with higher, more effective doses of radiopharmaceuticals with reduced toxicity. The developed platform will be evaluated in a preclinical setting to assess its efficacy and safety.

Keywords:Targeted radionuclide therapy, pretargeting, VHH

Disciplines:Radiopharmacy

Project type:PhD project